Topical Application of Phlorotannins from Brown Seaweed Mitigates Radiation Dermatitis in a Mouse Model.
Administration, Cutaneous
Animals
Anti-Inflammatory Agents
/ administration & dosage
Antioxidants
/ administration & dosage
Disease Models, Animal
Female
Inflammation Mediators
/ metabolism
Mice, Inbred BALB C
Oxidative Stress
/ drug effects
Radiodermatitis
/ drug therapy
Seaweed
/ chemistry
Signal Transduction
Skin
/ drug effects
Tannins
/ administration & dosage
Time Factors
Wound Healing
/ drug effects
inflammation
mouse model
phlorotannins
radiation dermatitis
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
22 Jul 2020
22 Jul 2020
Historique:
received:
03
07
2020
revised:
17
07
2020
accepted:
20
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
19
5
2021
Statut:
epublish
Résumé
Radiation dermatitis (RD) is one of the most common side effects of radiotherapy; its symptoms progress from erythema to dry and moist desquamation, leading to the deterioration of the patients' quality of life. Active metabolites in brown seaweed, including phlorotannins (PTNs), show anti-inflammatory activities; however, their medical use is limited. Here, we investigated the effects of PTNs in a mouse model of RD in vivo. X-rays (36 Gy) were delivered in three fractions to the hind legs of BALB/c mice. Macroscopic RD scoring revealed that PTNs significantly mitigated RD compared with the vehicle control. Histopathological analyses of skin tissues revealed that PTNs decreased epidermal and dermal thickness compared with the vehicle control. Western blotting indicated that PTNs augmented nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1 (HO-1) pathway activation but attenuated radiation-induced NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and inflammasome activation, suggesting the mitigation of acute inflammation in irradiated mouse skin. PTNs also facilitated fast recovery, as indicated by increased aquaporin 3 expression and decreased γH2AX (histone family member X) expression. Our results indicate that topical PTN application may alleviate RD symptoms by suppressing oxidative stress and inflammatory signaling and by promoting the healing process. Therefore, PTNs may show great potential as cosmeceuticals for patients with cancer suffering from radiation-induced inflammatory side effects such as RD.
Identifiants
pubmed: 32707897
pii: md18080377
doi: 10.3390/md18080377
pmc: PMC7460453
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antioxidants
0
Inflammation Mediators
0
Tannins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Oceans and Fisheries
ID : #20150220
Organisme : National Research Foundation of Korea
ID : #NRF-2018R1A2B2002835
Références
Acta Histochem. 2014 Jun;116(5):669-74
pubmed: 24751171
Asian Pac J Cancer Prev. 2013;14(8):4859-64
pubmed: 24083759
Food Chem Toxicol. 2009 Feb;47(2):410-7
pubmed: 19111593
Mar Drugs. 2020 Apr 11;18(4):
pubmed: 32290492
Mar Drugs. 2013 Jan 18;11(1):165-83
pubmed: 23334528
Qual Life Res. 2017 Jul;26(7):1713-1719
pubmed: 28238091
Phytother Res. 2008 Feb;22(2):238-42
pubmed: 17886227
J Radiat Res. 2010;51(5):511-7
pubmed: 20657159
Future Oncol. 2018 Feb;14(3):291-305
pubmed: 29153015
Exp Hematol. 2007 Apr;35(4 Suppl 1):96-104
pubmed: 17379094
Oncol Nurs Forum. 2004 Mar-Apr;31(2):237-47
pubmed: 15017440
Int J Radiat Biol. 2010 Oct;86(10):848-59
pubmed: 20883140
Biochem Biophys Res Commun. 2020 Feb 12;522(3):626-632
pubmed: 31785808
J Radiat Res. 2016 Sep;57(5):567-571
pubmed: 27242339
J Photochem Photobiol B. 2016 Sep;162:100-105
pubmed: 27362368
J Agric Food Chem. 2016 Jan 27;64(3):570-8
pubmed: 26730445
Food Chem. 2018 Aug 15;257:128-134
pubmed: 29622188
Am J Clin Dermatol. 2016 Jun;17(3):277-92
pubmed: 27021652
Curr Drug Discov Technol. 2020 Feb 05;:
pubmed: 32026778
Cancer Manag Res. 2018 Dec 21;11:167-177
pubmed: 30613164
Life Sci. 2006 Sep 5;79(15):1436-43
pubmed: 16737716
Front Immunol. 2019 May 07;10:1004
pubmed: 31134077
Vet Dermatol. 2012 Feb;23(1):51-6, e12
pubmed: 22040269
J Pain Symptom Manage. 2005 Nov;30(5):433-42
pubmed: 16310617
Environ Toxicol Pharmacol. 2011 Nov;32(3):325-35
pubmed: 22004951
Chem Biol Interact. 2010 May 14;185(3):215-26
pubmed: 20188716
Food Chem Toxicol. 2013 Sep;59:199-206
pubmed: 23774261
Int Wound J. 2016 Jun;13(3):390-3
pubmed: 24947011
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1141-1152
pubmed: 31063799
J Histochem Cytochem. 2013 Jan;61(1):63-74
pubmed: 23117934
Anticancer Res. 2017 Oct;37(10):5343-5353
pubmed: 28982842
BMC Cancer. 2018 Sep 6;18(1):873
pubmed: 30189840
Int J Biochem Cell Biol. 2010 Feb;42(2):297-305
pubmed: 19931411
Front Pharmacol. 2018 Mar 27;9:287
pubmed: 29636694
Radiat Res. 2007 Jan;167(1):43-50
pubmed: 17214513
J Pharmacol Exp Ther. 2017 Aug;362(2):243-253
pubmed: 28515158
Toxicol In Vitro. 2009 Sep;23(6):1123-30
pubmed: 19490939
Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):585-597
pubmed: 27825853
Biochem Biophys Res Commun. 2020 Jul 23;528(2):305-310
pubmed: 32475638
Mar Drugs. 2015 Jan 16;13(1):509-28
pubmed: 25603345
Expert Rev Clin Pharmacol. 2013 Nov;6(6):641-9
pubmed: 24164612
Photochem Photobiol. 2010 Sep-Oct;86(5):1056-63
pubmed: 20670358
Mar Drugs. 2020 Apr 21;18(4):
pubmed: 32326173
J Clin Oncol. 2008 May 1;26(13):2085-92
pubmed: 18285602
J Invest Dermatol. 2008 Jun;128(6):1365-74
pubmed: 18049451